CGAS and neoplasm: Notably, preclinical research has emphasized the immunomodulatory capabilities of PARPi in activating the cytoplasmic DNA recognition cGAS-STING pathway, leading to elevated PD-L1 expression, a type-1 interferon (IFN-I) response, and tumor infiltration by lymphocytes 46-49.